Blood Coagulation/ Clotting prevents excessive bleeding during an injury or surgery. Coagulation tests measure blood’s ability and the duration it takes to clot. These tests help clinicians to assess the risk of excessive bleeding or developing clots (thrombosis) in the blood vessels. Clinicians frequently order coagulation tests to assess blood clotting function in patients before performing surgeries or in treatments of disorders related to arteries.

Coagulation tests help in determining the probable bleeding rate in the perioperative or postoperative period. These laboratory tests are also helpful in elucidating the cause of unexplained bleeding and predicting blood clotting or thrombosis in the absence of vessel injury. The global blood coagulation testing market appears to be well-established with the availability of many well-described assays. The market is growing pervasively over the past few years.

According to Market Research Future (MRFR), the global coagulation testing market is expected to grow exponentially by 2023. In its recently published study, MRFR also asserts that the market would register approximately 6.5% CAGR throughout the assessment period (2017 – 2023). Growing liver failure cases foster market growth, driving the demand for blood coagulation tests.

The market is predominantly driven by the rising prevalence of the liver disease, von Willebrand disease (vWF), and hemophilia and increasing per capita healthcare expenses. Significant technological strides in testing devices led by the substantial investments transpired by the private public organization are escalating the market on a global level, driving RD activities.

Well-spread awareness about various diseases and disorders related to liver, hemophilia, and vWF driven through various governmental initiatives acts as a major tailwind pushing the growth of the coagulation testing market, further. Additional factors, such as the increasing population, sedentary lifestyle, and urbanization support market growth.

Conversely, high costs of these tests and poor reimbursement policies are the two significant growth constraining factors. Moreover, the unmet clinical needs and the unavailability of external funding, especially in developing regions, obstruct the growth of the market. Nevertheless, improving economic conditions would support the growth of the market, availing access to excellent healthcare, and increasing healthcare expenditures.

Request Free Sample Copy at:

https://www.marketresearchfuture.com/sample_request/970

Blood Coagulation Testing Market – Segmentations

The report is segmented into five key market dynamics to widen the scope of understanding,

By Product                : Automated Testing, Semi-Automated Testing, and Clinical Laboratory Testing, among others.

By Application         : Acquired Bleeding Disorders, Congenital Bleeding Disorders, Hemophilia, and Von Willebrand Disease, among others.

By Test Type : Testing Kits {segmented into prothrombin time (PT), activated clotting time, D dimer, and fibrinogen (FIB)}, and others.

By End-users            : Hospitals, Academic Institutions, and Diagnostic Laboratories, among others.

By Regions                : Europe, North America, APAC, and the Rest-of-the-World (RoW).

Blood Coagulation Testing Market – Regional Analysis

North America is forecasted to retain its leading position in the global blood coagulation testing market throughout the review period. The presence of prominent market players and well-developed healthcare sectors in the region influence the market growth, significantly.

Besides, rising prevalence of the liver disease, von Willebrand disease (vWF), and hemophilia alongside, the high healthcare expenditures, especially in the US Canada, drive the market growth. Simultaneously, huge technological advances and increasing government support for research development are impacting the growth of the regional market, positively.

Europe takes the second-leading position in the global coagulation testing market. Factors such as the presence of a large number of well-established players and their investments in RD activities foster the growth of the regional market. Well-spread awareness driven by private and public organizations about various diseases and disorders related to liver, hemophilia, and vWF acts as a major tailwind for the European coagulation testing market.

The Asia Pacific blood coagulation testing market is rapidly emerging as a lucrative market globally. Factors substantiating the growth market include increasing healthcare expenditures and favorable government policies in the region. Substantial investment transpired into RD activities, rapidly developing healthcare infrastructure and government support boost the growth of the APAC blood coagulation testing market. Furthermore, huge patient population alongside the augmenting demand for quality medical would increase the growth of the regional market.

Global Blood Coagulation Testing Market – Competitive Analysis

Fiercely competitive blood coagulation testing market appears fragmented due to many large and small players churning the competition in the market. Through the strategic partnership, acquisition, expansion, product technology launch, and collaboration, these players try to gain a competitive edge.

Major Players:

Players leading the global blood coagulation testing market include including Alere Inc. (US), Siemens Healthcare Private Limited (Europe), F. Hoffmann-La Roche Ltd. (Europe), CoaguSense, Inc. (US), HomoSonics LLC. (US), Accriva Diagnostics (US), Instrumentation Laboratory (US), SenGenix Inc. (US), iLine Microsystems. (Europe), Bio/Data Corporation (US), and Sienco, Inc. (US), among others. 

Industry, Innovation Related News 

August 20, 2019 ---- Q-Sera Pty Ltd (Australia), a leading global medical device company announced the receiving of a Notice of Allowance from the US Patent Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes. The technology is based on lead active RAPClotTM, which can rapidly produce high-quality serum for biochemical analysis, even if the blood sample contains anti-coagulants which affect around 10 percent of hospital patients.

March 27, 2019 ---- HemoSonics, LLC (the US), leading global medical devices and clinical tools company, announced that it has won FDA de novo approval for its Quantra QPlus System and accompanying QPlus cartridge for point-of-care coagulation analysis. Quantra QPlus System provides easy rapid coagulation status. The system gives initial results in about five minutes and the rest within about fifteen minutes.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/blood-coagulation-testing-market-970

Browse More Related Report:

Crohn’s Disease Market

https://www.marketresearchfuture.com/reports/crohns-disease-market-2344

Migraine Market

https://www.marketresearchfuture.com/reports/migraine-market-2381

Healthcare Biometrics Market

https://www.marketresearchfuture.com/reports/healthcare-biometrics-market-2450

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com